PAG
RNTX

Private Advisor Group’s Rein Therapeutics RNTX Stock Holding History

Private Advisor Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50
Closed -$1K – 3507
2020
Q2 		$1K Buy
+50
New +$815 ﹤0.01% 3776

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Private Advisor Group's RNTX Position: Q3 2020 in Review

Private Advisor Group sold out of Rein Therapeutics (RNTX) in Q3 2020, closing a stake of 50 shares — an estimated $1K sold.

Private Advisor Group first reported a position in RNTX in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 28 funds tracked by Wall St. Rank hold RNTX as of Q3 2020.

  • Private Advisor Group reported no remaining Rein Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 50 Rein Therapeutics shares in Q3 2020, an estimated $1K.
  • Private Advisor Group first reported a position in Rein Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Rein Therapeutics position peaked at $1K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.